MetaCap

Agios Pharmaceuticals (AGIO) vs Schrodinger (SDGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Schrodinger (SDGR) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 39.2% versus a gain of 9.4%. Over five years, AGIO leads with a -24.3% price change compared with -42.0% for SDGR. Schrodinger is the larger company by market cap ($1.72 billion vs $1.65 billion), about 1.0 times the size, while Agios Pharmaceuticals is growing revenue faster (+48.0% vs +23.3%).

Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -764.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO+9.35%SDGR+39.22%
+110%+35%-40%
Nov 21, 20251 yearNov 20, 2026
AGIO-27.79%SDGR-43.80%
+68%-6%-80%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus SDGR key metrics
MetricAGIOSDGR
Share price$27.60$22.93
Market cap$1.65B$1.72B
1-day change-4.03%-12.95%
YTD return+1.40%+28.24%
1-year return+9.35%+39.22%
5-year return-24.28%-42.01%
EPS (TTM)$-6.31$-0.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M$255.87M
Revenue growth (YoY)+48.03%+23.29%
Net income (latest FY)$-412.78M$-103.27M
Gross margin88.26%55.74%
Operating margin-873.87%-65.23%
Net margin-764.01%-40.36%
52-week high$44.09$34.00
52-week low$24.16$10.95
Distance from 52-week high-37.40%-32.56%
Analyst consensusbuybuy
Avg. price target upside+67.07%+46.40%
Average volume1.06M2.08M
Shares outstanding59.81M65.91M
Employees539850
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SDGR has outperformed AGIO by 29.9 percentage points over the past year.
  • Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
  • Agios Pharmaceuticals grew revenue faster in its latest fiscal year (+48.03% vs +23.29%).

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

AGIO vs SDGR FAQ

Which is bigger, Agios Pharmaceuticals or Schrodinger?

Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.65B for Agios Pharmaceuticals (AGIO).

Which stock has performed better over the past year, AGIO or SDGR?

SDGR returned +39.22% over the past 12 months, compared with +9.35% for AGIO (price return, excluding dividends). Past performance does not predict future results.

Are Agios Pharmaceuticals and Schrodinger in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons